高飞 冯凯 马钰涛 郁邦兴 买尔旦·买买提 热比亚·努力 ?单骄宇

    [摘要] 在感染的控制与治疗中，免疫耐受往往影响疗效。吲哚胺2，3-双加氧酶(IDO)介导的免疫耐受与Toll样受体2/4(TLR2/4)启动的免疫应答可同时存在。IDO通过两种途径抑制T细胞增殖或促进T细胞凋亡，即介导色氨酸代谢、促进调节性T细胞(Treg)的高表达。增多的Tregs与DC表面受体结合又可促进IDO表达。目前IDO抑制剂的初期研发、应用已证明在肿瘤治疗中起到一定作用。本文对TLR2/4和IDO的作用通路进行综述从而为靶向治疗提供一定的思路。

    [关键词] Toll样受体;吲哚胺2，3-双加氧酶;免疫逃避;感染性疾病

    [中图分类号] R378 ? ? ? ? ?[文献标识码] A ? ? ? ? ?[文章编号] 1673-7210(2019)05(b)-0026-04

    [Abstract] In control or treatment of infection diseases， immune tolerance can affect the efficacy of immunotherapy. At the same time， indoleamine 2， 3-dioxygenase (IDO)-mediated immune tolerance and TLR2/4-initiated immune response often co-exist. IDO inhibits T cell proliferation or promotes T cell apoptosis by mediating tryptophan metabolism and promoting high expression of regulatory T cells(Tregs). At the same time， increased Tregs can promote the expression of IDO by binding to the receptors of DCs. At present， IDO inhibitors have been proved to play an important role in cancer treatment. This article reviews the pathways of TLR2/4 and IDO， which provides some ideas for future targeted therapy. ......